
    
      The drug being tested in this study is called TAK-438. TAK 438 is being tested to assess the
      effect of multiple oral doses of clarithromycin on the pharmacokinetics of TAK-438.

      The study will enroll approximately 16 healthy adult male participants of non-Japanese
      origin. Participants will be assigned:

        -  TAK-438 40 mg

        -  Clarithromycin 500 mg

      All participants will be asked to take 2 tablet of TAK-438 20 mg orally, once on Days 1 and 8
      along with Clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.

      This single center trial will be conducted in Europe. The overall time to participate in this
      study is maximum of 44 days. Participants will be confined to site for 10 days, and a final
      visit after 4 days after discharge from the unit for a follow-up assessment.
    
  